Antimalarial Prescription Patterns and Adherence to the WHO 2024 Guidelines among Pregnant Women: A Case Study from a Nigerian Tertiary Hospital
Main Article Content
Abstract
Background: Adherence to the World Health Organization (WHO) treatment guidelines for malaria in pregnancy (MiP) is crucial for improved maternal and perinatal health outcomes. This study assessed antimalarial prescription patterns and adherence of each prescription to the WHO 2024 MiP guidelines using a Nigerian tertiary hospital as a case study.
Methods: A retrospective, cross-sectional study was conducted using antenatal care (ANC) records of pregnant women who attended ANC at FMC Makurdi in 2024. A total of 1,062 eligible prescriptions were selected via systematic random sampling and analysed using R. Descriptive statistics summarized patient demographics and treatment patterns. Adherence to guidelines was subsequently assessed.
Results: Among the 1,062 prescriptions analysed, the majority (96.1%) were for IPTp rather than acute treatment with most for women in their second (44.4%) or third trimester (55.0%). Overall, sulfadoxine-pyrimethamine (SP) was the most prescribed antimalarial medication during pregnancy (96.0%). Artemether-lumefantrine (AL, 92.5%) and SP (99.9%) were mostly prescribed for uncomplicated malaria and IPTp respectively. Adherence to treatment guidelines was high (99.4%); however, trimester-specific deviations were noted where most instances of non-compliance occurred in the first trimester.
Conclusion: While overall adherence to MiP guidelines was high at FMC Makurdi, specific deviations—particularly regarding first-trimester prescriptions and the use of Al for prevention—were observed. These findings underscore the need for continuous education and reinforcement of guideline adherence among healthcare providers to ensure optimal and safe antimalarial management especially in malaria-endemic settings.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
How to Cite
References
1. CDC. Clinical Guidance: Malaria Diagnosis & Treatment in the U.S. Malaria. April 3, 2024. Accessed April 25, 2025. https://www.cdc.gov/malaria/hcp/clinical-guidance/pregnant-women.html
2. WHO. WHO guidelines for malaria. 2024. Accessed April 25, 2025. https://www.who.int/publications/i/item/guidelines-for-malaria
3. WHO. World malaria report 2024. 2024. Accessed April 25, 2025. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024
4. Saito M, Briand V, Min AM, McGready R. Deleterious effects of malaria in pregnancy on the developing fetus: a review on prevention and treatment with antimalarial drugs. The Lancet Child & Adolescent Health. 2020;4(10):761-774. doi:10.1016/S2352-4642(20)30099-7
5. Alemu A, Shiferaw Y, Addis Z, Mathewos B, Birhan W. Effect of malaria on HIV/AIDS transmission and progression. Parasites & Vectors. 2013;6(1):18. doi:10.1186/1756-3305-6-18
6. Roberds A, Ferraro E, Luckhart S, Stewart VA. HIV-1 Impact on Malaria Transmission: A Complex and Relevant Global Health Concern. Front Cell Infect Microbiol. 2021;11. doi:10.3389/fcimb.2021.656938
7. National Malaria Elimination Programme. National Guidelines for the Diagnosis & Treatment of Malaria. Federal Ministry of Health, Nigeria; 2020. Accessed May 1, 2025. https://drive.google.com/file/d/1pxGgYsCjEWYDQ5-2GM5PSeeWHXww7erK/view?usp=sharing&usp=embed_facebook
8. Ezenduka C, Nworgu C, Godman BB, Massele A, Esimone C. Antimalarial treatment patterns among pregnant women attending antenatal care clinics in south east Nigeria and the future implications. International Journal of Clinical Practice. 2016;70(12):1041-1048. doi:10.1111/ijcp.12913
9. Ameh S, Owoaje E, Oyo-Ita A, et al. Barriers to and determinants of the use of intermittent preventive treatment of malaria in pregnancy in Cross River State, Nigeria: a cross-sectional study. BMC Pregnancy and Childbirth. 2016;16(1):99. doi:10.1186/s12884-016-0883-2
10. Nishan MDNH, Akter K. Coverage and determinants of Intermittent Preventive Treatment in pregnancy (IPTp) in Cameroon, Guinea, Mali, and Nigeria. PLOS ONE. 2024;19(11):e0313087. doi:10.1371/journal.pone.0313087
11. Kalu GO, Francis JM, Ibisomi L, Chirwa T, Kagura J. Factors associated with the uptake of Intermittent Preventive Treatment (IPTp-SP) for malaria in pregnancy: Further analysis of the 2018 Nigeria Demographic and Health Survey. PLOS Glob Public Health. 2023;3(2):e0000771. doi:10.1371/journal.pgph.0000771
12. ICF. The DHS Program STATcompiler. Accessed October 18, 2025. https://www.statcompiler.com/en/
13. Pons-Duran C, Llach M, Sacoor C, et al. Coverage of intermittent preventive treatment of malaria in pregnancy in four sub-Saharan countries: findings from household surveys. Int J Epidemiol. 2020;50(2):550-559. doi:10.1093/ije/dyaa233
14. Efunshile M, Amoo AOJ, Akintunde GB, Ojelekan OD, König W, König B. Use and effects of malaria control measures in pregnancy in Lagos, Nigeria. Korean J Parasitol. 2011;49(4):365-371. doi:10.3347/kjp.2011.49.4.365
15. Akpan U, Edet E, Arogundade K, Akpanika C, Ekott M, Etuk S. Implementation of the Revised National Malaria Control Guidelines: Compliance and Challenges in Public Health Facilities in a Southern Nigerian State. Health�Serv�Insights. 2023;16:11786329231211779. doi:10.1177/11786329231211779
16. Ogba P, Baumann A, Chidwick H, Banfield L, DiLiberto DD. Barriers and facilitators to access and uptake of intermittent preventive treatment with sulfadoxine-pyrimethamine among pregnant women in Nigeria: a scoping review. Malariaworld J. 2022;13:4.
17. Sangho O, Tounkara M, Whiting-Collins LJ, Beebe M, Winch PJ, Doumbia S. Determinants of intermittent preventive treatment with sulfadoxine–pyrimethamine in pregnant women (IPTp-SP) in Mali, a household survey. Malaria Journal. 2021;20(1):231. doi:10.1186/s12936-021-03764-5
18. Wikipedia. Makurdi. In: Wikipedia. 2025. Accessed July 24, 2025. https://en.wikipedia.org/w/index.php?title=Makurdi&oldid=1292507521
19. WorldAtlas. The Longest Rivers In Nigeria. WorldAtlas. August 1, 2019. Accessed July 24, 2025. https://www.worldatlas.com/articles/longest-rivers-in-nigeria.html
20. Abatur SC, Oden GE, Okwori JM, et al. Knowledge of Diabetic Retinopathy Amongst Pharmacists in a Nigerian Tertiary Health Facility. Nigerian Journal of Clinical Pharmacy and Therapeutics. 2024;3(1). doi:https://njcpt.com.ng/101.1.2.47
21. R Core Team. R: A Language and Environment for Statistical Computing. Published online 2025. https://www.R-project.org/
22. Arute JE, Ojieabu W, Patani-Okolosi OE, Iwor C. Prescribing trends of antimalarial drugs in a primary health care facility in Delta State. World Journal of Pharmaceutical Research. 2016;5(5). Accessed May 6, 2025. https://www.researchgate.net/profile/John-Arute/publication/302487884_Prescribing_trend_of_antimalarial_in_a_primary_health_care_facility_in_delta/links/5730a7c908aed286ca0db870/Prescribing-trend-of-antimalarial-in-a-primary-health-care-facility-in-delta.pdf
23. Ballo M, Traoré K, Sidibé S, et al. Preventive and Curative treatment of malaria during pregnancy in Mali: Evaluation of the Healthcare Professionals based on the Malian National Malaria Control Program (NMCP) Guidelines. Journal of Drug Delivery and Therapeutics. 2021;11(5-S):71-76. doi:10.22270/jddt.v11i5-S.5092
24. Fordjour F, Buabeng KO. Antimalarial usage in pregnancy: a cross-sectional study in the Bono regions of Ghana. International Journal of Technology Management. 2020;1(7). Accessed May 7, 2025. https://www.academia.edu/50259701/Antimalarial_Usage_in_Pregnancy_a_Cross_Sectional_Study_In_The_Bono_Regions_of_Ghana
25. Mohamoud AM, Yousif MEA, Saeed OK. Factors Affecting Adherence to National Malaria Treatment Guidelines in the Diagnosis, Treatment and Prevention of Malaria in Pregnancy among Healthcare Workers in Public Health Facilities in Jowhar District, Somalia. Health. 2022;14(11):1114-1129. doi:10.4236/health.2022.1411079
26. Omale UI. Knowledge, attitude, and practice of the National Guidelines for Diagnosis and Treatment of Malaria among medical doctors in Ebonyi state, Nigeria: A cross-sectional survey. PLoS One. 2021;16(9):e0257600. doi:10.1371/journal.pone.0257600
27. Yaya S, Uthman OA, Amouzou A, Bishwajit G. Use of Intermittent Preventive Treatment among Pregnant Women in Sub-Saharan Africa: Evidence from Malaria Indicator Surveys. Tropical Medicine and Infectious Disease. 2018;3(1):18. doi:10.3390/tropicalmed3010018
28. Arulogun OS, Okereke CC. Knowledge and practices of intermittent preventive treatment of malaria in pregnancy among health workers in a southwest local government area of Nigeria. JMMS. 2012;3(6):415-422.
29. Bello OO, Oni O. Health Workers’ Awareness and Knowledge of Current Recommendation of Intermittent Preventive Treatment in Pregnancy in South-Western Nigeria. Ethiop J Health Sci. 2020;30(1):125-134. doi:10.4314/ejhs.v30i1.16
30. Ikpeama EC, Udealor PC, Onwuka CI. Malaria in pregnancy: Assessment of doctors’ conformity to monthly intermittent preventive treatment in a Sub-Saharan African Country. International Journal of Medicine and Health Development. 2022;27(4):356. doi:10.4103/ijmh.ijmh_36_22
31. Recht J, Clark R, González R, Dellicour S. Safety of Artemisinin and Non-Artemisinin Antimalarials in the First Trimester of Pregnancy: Review of Evidence. World Health Organization; 2023. https://www.who.int/publications/i/item/9789240069404
32. Ugwu EO, Iferikigwe ES, Obi SN, Ugwu AO, Agu PU, Okezie OA. Anti-malaria prescription in pregnancy among general practitioners in Enugu state, south east Nigeria. Nigerian Medical Journal. 2013;54(2):96. doi:10.4103/0300-1652.110038
33. Mahamar A, Smit MJ, Sanogo K, et al. Artemether–lumefantrine with or without single-dose primaquine and sulfadoxine–pyrimethamine plus amodiaquine with or without single-dose tafenoquine to reduce Plasmodium falciparum transmission: a phase 2, single-blind, randomised clinical trial in Ouelessebougou, Mali. The Lancet Microbe. 2024;5(7):633-644. doi:10.1016/S2666-5247(24)00023-5
34. González R, Nhampossa T, Mombo-Ngoma G, et al. Safety and efficacy of dihydroartemisinin–piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases. 2024;24(5):476-487. doi:10.1016/S1473-3099(23)00738-7
35. Kakuru A, Jagannathan P, Muhindo MK, et al. Dihydroartemisinin–Piperaquine for the Prevention of Malaria in Pregnancy. N Engl J Med. 2016;374(10):928-939. doi:10.1056/NEJMoa1509150
36. Madanitsa M, Barsosio HC, Minja DTR, et al. Effect of monthly intermittent preventive treatment with dihydroartemisinin–piperaquine with and without azithromycin versus monthly sulfadoxine–pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial. The Lancet. 2023;401(10381):1020-1036. doi:10.1016/S0140-6736(22)02535-1
37. Conrad MD, Rosenthal PJ. Antimalarial drug resistance in Africa: the calm before the storm? The Lancet Infectious Diseases. 2019;19(10):e338-e351. doi:10.1016/S1473-3099(19)30261-0